The European Commission’s compulsory licensing proposals are sensible but do not go far enough
An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...
Why The Request By Least Developed Countries For An Extension Of The Transitional Period...
On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...
Legal tools that lower medicines prices have expanded access to medicines for over two...
LONDON, UK: Millions of people are priced out of access to life-saving medicines. Use of legal tools to reduce prices has been under-reported and...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...
Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect...
The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...
Imagine if health and trade ministers would meet in one room this week
A earlier version of this commentary was published on 28 November 2021 by Barron's.
This is a time of missed opportunities. This week, trade ministers...
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. »
L’augmentation croissante du prix...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...